Quantifying DNA damage is mandatory to assess potential adverse effects of candidate drugs or molecules or extracts developed in the dermo-cosmetic industry, but also to assess the efficacy of therapeutic approaches with the aim of producing tumor cell genotoxicity in cancer treatment.

The comet assay is a sensitive, well established technique for quantifying DNA damage in eukaryotic cells. Compatible with the detection of a wide range of DNA damaging agents, its principle consists in the migration of fragmented DNA in an electrophoresis gel (damaged DNA forming the tail of the comet), while intact DNA moves at a slower rate (head of the comet). The percentage of fragmented DNA in the comet tail is a direct measure of DNA damage.

View and download on Slideshare (low quality) :
http://fr.slideshare.net/hcspharma/development-of-an-automated-comet-assay-for-genotoxicity-assessment-on-tk6-cell-line

Ask for high quality link by putting your email below


1 Comment

Genotoxicity assay development in collaboration with Galderma R&D | HCS-pharma · June 7, 2016 at 9:01 am

[…] ELRIGfr event in Rennes, We had the opportunity to present our work on genotoxicity assay (comet assay on TK6 & gH2AX on keratinocytes and HepG2) in collaboration with the team of in vitro of Galderma […]

Leave a Reply